Newsroom

Sorted by: Latest

-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Capital Strength UCITS ETF 07.05.2026 FTCS. IE00BL0L0D23 325,002.00 USD 10,464,882.29 32.199  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Value Line Dividend Index UCITS ETF 07.05.2026 FVD. IE00BKVKW020 250,002.00 USD 7,214,363.12 28.857  ...
-

KAYTUS Launches All-QLC Flash Storage at AI EXPO 2026 for 10,000-GPU Clusters

SINGAPORE--(BUSINESS WIRE)--KAYTUS Launches All-QLC Flash Storage at AI EXPO 2026 for 10,000-GPU Clusters...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Capital Strength ESG Leaders UCITS ETF 07.05.2026 FCSG IE00BKPSPT20 1,025,002.00 USD 43,937,173.57 42.865  ...
-

Beneq Appoints Dr. Jason Harrison as Chief Executive Officer

ESPOO, Finland--(BUSINESS WIRE)--Beneq, the home of atomic layer deposition (ALD), appoints Dr. Jason Harrison as Chief Executive Officer....
-

From Engineering Intent to Validated Design in Minutes: SimScale Opens Engineering AI Agents to All Enterprise Teams

MUNICH--(BUSINESS WIRE)--SimScale, the AI-native cloud platform for engineering simulation, today opened enterprise waitlist access to its guided pilot service for Engineering AI agents — autonomous simulation orchestration tools that extract technical intent from engineering specifications and execute the complete validation workflow, from CAD preparation and meshing to solver configuration and final report. The announcement marks the transition of Engineering AI from strategic customer deploy...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 07.05.2026 FXGB LN IE00BD5HBR05 37,992.00 GBP 768,905.63 27.586  ...
-

Faraday Future Teases New Milestone with Announcement Coming on May 10th

LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today has released a new social teaser titled “The Next Climb Begins,” signaling the Company’s next chapter and inviting audiences to stay tuned for an upcoming announcement on May 10th. The teaser highlights four symbolic phases in FF’s journey: “The Great Ascent” from May 2014 to September 2021, “Lost in...
-

Une avancée majeure en médecine régénérative, la thérapie cellulaire BEES-HAUS : effet paracrine et prise de greffe cellulaire, deux mécanismes qui, combinés, permettent de soigner la sténose urétrale. Les résultats de sa version simplifiée, ...

TOKYO--(BUSINESS WIRE)--  Une avancée majeure en médecine régénérative, la thérapie cellulaire BEES-HAUS : effet paracrine et prise de greffe cellulaire, deux mécanismes qui, combinés, permettent de soigner la sténose urétrale. Les résultats de sa version simplifiée, BHES-HAUS, seront présentés lors de l’AUA 2026   Une découverte scientifique révolutionnaire, dévoilant le mécanisme de cicatrisation réussi de la sténose urétrale grâce à la thérapie cellulaire BEES-HAUS, a été rapportée par des m...
-

Avance pionero en medicina regenerativa, la terapia celular BEES-HAUS: El efecto paracrino y el injerto celular se combinan para reparar la estenosis uretral. Los resultados de su versión simplificada, BHES-HAUS, se presentarán en la AUA 2026

TOKIO--(BUSINESS WIRE)--Un grupo de médicos y científicos de la India y Japón ha publicado un descubrimiento científico pionero que esclarece el mecanismo de cicatrización exitosa de la estenosis uretral mediante la terapia celular BEES-HAUS. Este logro histórico en medicina regenerativa, que demuestra seguridad y eficacia clínicas, es el primero de su tipo en el que se utilizó un enfoque híbrido que combina dos grupos de células epiteliales bucales autólogas, un grupo cultivado en 2D y otro en...